Capricorn Scientific GmbH is a manufacturer of sterile solutions, reagents and chemical mixtures for cell culture and was formed in 2016 from the merger of Diagnovum GmbH and the former Capricorn Scientific GmbH. The company produces, fills, packages and distributes cell culture products intended for diagnostic use without contact with the human or animal body, and invests in developing biotechnological and biochemical preparations. As of 31/12/2024 its products were exported to more than 70 countries, and its customer base is split between research (academic) customers and industrial biotech customers, with the latter accounting for about 30% of revenue. At the reporting date the company employed 65 people and during the COVID‑19 pandemic built a pharmaceutical production facility with total investments of €6.5 million.
Gegenstand des Unternehmens sind die Herstellung, Abfüllung, Verpackung und der Vertrieb von Zellkulturprodukten und Präparaten, die zur diagnostischen Verwendung ohne Berührung mit dem menschlichen oder tierischen Körper bestimmt sind; die Errichtung von Zweigniederlassungen und Beteiligungen an gleichartigen Unternehmen; die Entwicklung neuer technologischer, biotechnologischer und biochemischer Präparate, Substanzen und Verfahren.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 2446 (as of 30 October 2026)
| Name | Type | City |
|---|---|---|
| Harry Brack | Geschäftsführer(in) | Ebsdorfergrund |
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 2446 (as of 30 October 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | Rohergebnis€7.4M2 | €123,215 | €11,523,883 | — |
| 2023 | Rohergebnis€7.5M2 | €334,731 | €12,360,602 | — |
| 2022 | Rohergebnis€7M2 | €764,805 | €12,363,763 | — |
| 2021 | ≤ €12M1 | €956,458 | €8,870,350 | — |
| 2020 | small company1 | €707,159 | €5,480,102 | — |
| 2019 | small company1 | €280,335 | €4,257,959 | — |
| 2018 | small company1 | €209,584 | €3,605,609 | — |
| 2017 | small company1 | €233,452 | €3,511,439 | — |
| 2016 | small company1 | €223,603 | €2,666,410 | — |
| 2015 | small company1 | €72,076 | €1,848,241 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Marburg Local Court, HRB 2446 (as of 30 October 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €3,705,494 | 87.3% |
| Depreciation | €337,609 | 8.0% |
| Interest & Similar | €202,761 | 4.8% |
